Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Payables (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Payables data on record, last reported at $40.5 million in Q3 2025.

  • For Q3 2025, Payables rose 18.93% year-over-year to $40.5 million; the TTM value through Sep 2025 reached $40.5 million, up 18.93%, while the annual FY2024 figure was $30.5 million, 19.95% up from the prior year.
  • Payables reached $40.5 million in Q3 2025 per AMPH's latest filing, down from $41.9 million in the prior quarter.
  • Across five years, Payables topped out at $175.9 million in Q1 2025 and bottomed at $18.8 million in Q2 2023.
  • Average Payables over 5 years is $75.3 million, with a median of $88.9 million recorded in 2023.
  • Peak YoY movement for Payables: crashed 80.72% in 2023, then skyrocketed 596.75% in 2024.
  • A 5-year view of Payables shows it stood at $89.5 million in 2021, then dropped by 5.92% to $84.2 million in 2022, then plummeted by 69.8% to $25.4 million in 2023, then rose by 19.95% to $30.5 million in 2024, then skyrocketed by 32.86% to $40.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $40.5 million in Q3 2025, $41.9 million in Q2 2025, and $175.9 million in Q1 2025.